Novavax (NVAX) is readying its forces to be a fully commercially-licensed company by the end of 2023, with a strong balance sheet and the workforce to achieve the endpoint.
This follows the company’s bumpy ride throughout the pandemic, with investor sentiment significantly down on the company.
It’s a bit of deja vu for outgoing CEO Stanley Erck, who spoke with Yahoo Finance at the annual JPMorgan Healthcare Conference in San Francisco this week.
In January 2020, at the beginning of the…
Source link
